Enveric Biosciences Secures New Patent for Neuroplastogenic Small-Molecule Therapeutics
Cambridge, MA, January 15, 2025 – Enveric Biosciences, a pioneering biotechnology company focused on the development of innovative neuroplastogenic small-molecule therapeutics for depression, anxiety, and addiction disorders, is thrilled to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,195,439 (the ‘439 patent) on January 14, 2025. This patent, entitled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives,” covers a new class of compounds with significant therapeutic potential.
Impact on Enveric Biosciences
The issuance of the ‘439 patent represents a critical milestone for Enveric Biosciences as it strengthens the Company’s intellectual property portfolio and reinforces its position as a leader in the development of novel neuroplastogenic small-molecule therapeutics. This patent provides Enveric with exclusive rights to develop, manufacture, and commercialize these innovative compounds for the treatment of depression, anxiety, and addiction disorders. The Company’s research and development team will continue to explore the therapeutic potential of these compounds, aiming to bring new and effective treatments to patients suffering from these debilitating conditions.
Global Implications
The ‘439 patent’s issuance is expected to have a significant impact on the global biotech industry, particularly in the area of neurotherapeutics. The new class of compounds covered by this patent offers a unique approach to treating depression, anxiety, and addiction disorders. These conditions affect millions of people worldwide, and the development of new and effective treatments is a pressing need. Enveric’s innovative approach to addressing these disorders through neuroplastogenic small-molecule therapeutics could pave the way for a new generation of treatments, offering hope and relief to those suffering from these conditions.
Potential Benefits for Patients
The neuroplastogenic small-molecule therapeutics covered by the ‘439 patent have the potential to offer several benefits to patients. These compounds are designed to enhance neuroplasticity, the brain’s ability to adapt and form new neural connections. This capability is crucial for the treatment of depression, anxiety, and addiction disorders, as these conditions often involve impairments in neural plasticity. By targeting these impairments, Enveric’s therapeutics could help restore normal brain function and improve patients’ overall well-being.
Conclusion
The issuance of U.S. Patent No. 12,195,439 by the USPTO marks an important step forward for Enveric Biosciences as it strengthens the Company’s intellectual property portfolio and underscores its commitment to developing innovative neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The global implications of this patent are significant, as it could lead to the development of new and effective treatments for millions of people worldwide who suffer from these debilitating conditions. Enveric’s dedication to advancing neuroscience research and its innovative approach to addressing these disorders through neuroplastogenic small-molecule therapeutics offers a glimmer of hope for those seeking relief from the burden of depression, anxiety, and addiction.
- Enveric Biosciences secures new patent for neuroplastogenic small-molecule therapeutics
- Patent covers Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives
- Strengthens Enveric’s intellectual property portfolio
- Reinforces Enveric’s position as a leader in neuroplastogenic therapeutics
- New class of compounds could lead to new generation of treatments for depression, anxiety, and addiction disorders
- Global implications are significant, offering hope for millions suffering from these conditions
